We are live on ! Find out more
NI

Nextech Invest Portfolio holdings

AUM $1.42B
1-Year Est. Return 304.47%
This Fund
S&P 500
This Quarter Est. Return
+32.13%
1 Year Est. Return
+304.47%
3 Year Est. Return
+631.11%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$528M
AUM Growth
+$98.1M
Cap. Flow
+$28.3M
Cap. Flow %
5.36%
Top 10 Hldgs %
93.84%
Holding
16
New
1
Increased
2
Reduced
1
Closed
–

Top Buys

Rank Stock Value
1
ORIC icon
Oric Pharmaceuticals
ORIC
+$12.6M
2
KYMR icon
Kymera Therapeutics
KYMR
+$11.7M
3
ALMS
Alumis Inc
ALMS
+$6.8M

Top Sells

Rank Stock Value
1
SPRY icon
ARS Pharmaceuticals
SPRY
+$2.81M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
RVMD icon
1
Revolution Medicines
RVMD
$39.1B
$280M 52.92%
7,601,087
– –
ORIC icon
2
Oric Pharmaceuticals
ORIC
$1.21B
$72.7M 13.76%
7,162,637
+1,876,923
+36% +$12.6M
TYRA icon
3
Tyra Biosciences
TYRA
$1.89B
$38.8M 7.35%
4,055,861
– –
TNGX icon
4
Tango Therapeutics
TNGX
$4.33B
$28.3M 5.36%
5,533,980
– –
KYMR icon
5
Kymera Therapeutics
KYMR
$8.87B
$14.9M 2.82%
+340,909
New +$11.7M
ZYME icon
6
Zymeworks
ZYME
$1.64B
$14M 2.65%
1,113,946
– –
RLAY icon
7
Relay Therapeutics
RLAY
$4.13B
$13.3M 2.52%
3,846,409
– –
SPRY icon
8
ARS Pharmaceuticals
SPRY
$575M
$12.9M 2.45%
741,729
-195,000
-21% -$2.81M
CRGX
9
DELISTED
CARGO Therapeutics
CRGX
$10.9M 2.06%
2,642,502
– –
ARVN icon
10
Arvinas
ARVN
$535M
$10.4M 1.96%
1,408,394
– –
ALMS
11
Alumis Inc
ALMS
$3.46B
$8.75M 1.66%
2,915,998
+1,439,000
+97% +$6.8M
CGEM icon
12
Cullinan Oncology
CGEM
$1.07B
$8.59M 1.63%
1,141,145
– –
SLN
13
Silence Therapeutics
SLN
$546M
$5.52M 1.05%
952,400
– –
CNTX icon
14
Context Therapeutics
CNTX
$54.8M
$4.86M 0.92%
7,419,355
– –
MRSN
15
DELISTED
Mersana Therapeutics
MRSN
$3.57M 0.68%
482,690
– –
BOLD
16
Boundless Bio
BOLD
$55.7M
$1.24M 0.23%
1,228,069
– –

Similar funds

BC
Broadwood Capital New York $1.42B AUM 34.72% 1-Year Est. Return
IHG
Insight Holdings Group New York $1.42B AUM 41.03% 1-Year Est. Return
PTC
Philadelphia Trust Company Philadelphia, Pennsylvania $1.42B AUM 43.77% 1-Year Est. Return
PPC
Park Presidio Capital San Francisco, California $1.43B AUM 21.33% 1-Year Est. Return
KCMH
Kontiki Capital Management (HK) Hong Kong $1.43B AUM 9.81% 1-Year Est. Return
APCM
Alaska Permanent Capital Management Anchorage, Alaska $1.43B AUM 13.12% 1-Year Est. Return
CBA
Coastal Bridge Advisors Westport, Connecticut $1.41B AUM 24.15% 1-Year Est. Return
KC
Kryger Capital London, United Kingdom $1.41B AUM 86.31% 1-Year Est. Return

Nextech Invest's Q2 2025 Portfolio in Review

As of Q2 2025, Nextech Invest held 16 positions worth $528M, up 23% from $430M the previous quarter. Its ten largest holdings account for 94% of the portfolio.

Nextech Invest deployed $28.3M of net new capital in Q2 2025, opening 1 new position and adding to 2 existing holdings. Its largest new stake was Kymera Therapeutics: 340,909 shares worth $14.9M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

On the sell side, the largest reduction was ARS Pharmaceuticals, an estimated $2.81M trimmed.

  • Nextech Invest's largest Q2 2025 buy was Kymera Therapeutics: 340,909 shares worth $14.9M.
  • Nextech Invest added most to Oric Pharmaceuticals in Q2 2025, an estimated $12.6M increase.
  • Nextech Invest's biggest Q2 2025 reduction was ARS Pharmaceuticals, cutting an estimated $2.81M.
  • Nextech Invest's ten largest holdings make up 94% of its $528M portfolio in Q2 2025.
  • Nextech Invest opened 1 new position and closed 0 in Q2 2025.
  • Nextech Invest's portfolio value rose 23% quarter-over-quarter to $528M.

Based on Nextech Invest's 13F filing for Q2 2025, filed 14 Aug 2025.